Alternative Oral Medications for Type 2 Diabetes

First-Line Alternatives to Metformin

The American Diabetes Association recommends sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, and α-glucosidase inhibitors as viable alternative oral medications for patients with type 2 diabetes mellitus who are allergic to metformin, with the choice depending on patient-specific factors including cardiovascular risk, weight considerations, and renal function 1, 2
Newer generation sulfonylureas, such as glimepiride, are effective alternatives with HbA1c reductions of 0.5-1.5% 2
DPP-4 inhibitors provide moderate glycemic control with minimal hypoglycemia risk when used as monotherapy, and are suitable for overweight patients due to their weight-neutral profile 2
SGLT2 inhibitors reduce HbA1c by 0.5-1.0% while providing additional benefits of weight loss and blood pressure reduction, and offer cardiovascular and renal protective benefits 2, 4

Thiazolidinediones decrease blood glucose by increasing insulin sensitivity with HbA1c reductions of 0.7-1.0%, but are contraindicated in heart failure, active liver disease, and severe osteoporosis due to risk of fluid retention and weight gain 2
α-Glucosidase inhibitors reduce postprandial glucose by inhibiting carbohydrate absorption, and are particularly suitable for patients whose diet consists mainly of carbohydrates 2
Glinides target postprandial glucose with shorter duration of action than sulfonylureas, and have a lower risk of hypoglycemia compared to sulfonylureas 2, 5

For patients with cardiovascular disease, SGLT2 inhibitors are preferred due to proven cardiovascular benefits, followed by DPP-4 inhibitors if SGLT2 inhibitors are contraindicated 4, 6
For overweight or obese patients, SGLT2 inhibitors promote weight loss, while DPP-4 inhibitors are weight neutral 2, 4
For elderly patients or those at high risk of hypoglycemia, DPP-4 inhibitors and SGLT2 inhibitors have minimal hypoglycemia risk, while α-Glucosidase inhibitors have very low hypoglycemia risk 2
For patients with renal impairment, DPP-4 inhibitors, especially linagliptin, require minimal dose adjustment, while SGLT2 inhibitors should be avoided or used with reduced doses in moderate-to-severe renal impairment 2, 4

The American College of Physicians recommends monitoring for drug-specific adverse effects, considering cost implications, and regularly reassessing therapy based on efficacy, tolerability, and development of comorbidities 1, 3, 6
For patients with HbA1c >9% or blood glucose ≥300 mg/dL, initiating dual therapy or insulin should be considered 1
If monotherapy fails to achieve glycemic targets within 3 months, combination therapy or insulin should be considered 1